ScreenerHero
GUBRAGubra A/S
CPH · DK · Healthcare · Biotechnology · gubra.dk
391.80DKK+2.83%Mkt Cap: 936.97M $P/E: —

Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Pre…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap936.97M $
Enterprise Value797.59M $
Revenue (TTM)384.06M $
Gross Profit372.39M $
Net Income (TTM)246.23M $
Revenue/Share23.59 USD
Last Price391.80 DKK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees300
CountryDK
SectorHealthcare
IndustryBiotechnology
ISINDK0062266474
Valuation
P/E (Trailing)—
P/E (Forward)17.89
PEG—
EV/EBITDA2.54
EV/Revenue2.08
P/S2.37
P/B5.43
EPS (TTM)102.70
EPS (Forward)21.30
52W Range
293.0037% of range557.50
52W High557.50 DKK
52W Low293.00 DKK
Profitability
Gross Margin96.96%
Oper. Margin-51.94%
EBITDA Margin81.76%
Profit Margin64.11%
ROE147.53%
ROA128.09%
Growth
Revenue Growth-0.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF249.41M $
CapEx (TTM)2.79M $
FCF Margin50.51%
FCF Yield20.70%
Net Debt-142.09M $
Net Debt/EBITDA-0.45
Balance Sheet
Debt/Equity0.09
Current Ratio13.63
Quick Ratio13.58
Book Value/Sh70.16 DKK
Cash/Share66.31 DKK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 DKK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateJun 30, 2025
Pay Date—
Analyst Consensus
Rating—
Target (Mean)501.00 DKK
Upside (mean)+27.9%
Target Range403.00 DKK – 600.00 DKK
DKK403.00+27.9% to meanDKK600.00
# Analysts3
Ownership
Shares Out.16.42M
Float6.26M
Insiders58.23%
Institutions11.82%
Technical
SMA 50354.07 (+10.7%)
SMA 200394.08 (-0.6%)
Beta0.32
S&P 52W Chg18.16%
Avg Vol (30d)21.30K
Avg Vol (10d)17.02K
Technical Indicators
RSI (14)57.4
MACD8.3371
MACD Signal7.4246
MACD Hist.+0.9125
BB Upper393.77 DKK
BB Middle371.59 DKK
BB Lower349.41 DKK
BB Width11.94%
ATR (14)17.35 DKK
Vol Ratio (20d)2.06x